On May 13, 2026, the Board of Directors of TAKE Solutions Limited convened to approve several transformative corporate actions. Central to these updates is the proposal to change the company’s name from “TAKE SOLUTIONS LIMITED” to “TAKE LIMITED,” pending member and regulatory approvals. Additionally, the board approved the appointment of M/s. A. Raghavendra Rao & Associates, Chartered Accountants, as Statutory Auditors to fill a casual vacancy. The meeting also addressed the modernization of the company’s foundational documents, specifically adopting a new Memorandum of Association (MOA) to align with the Companies Act, 2013.

The alteration of the MOA includes the insertion of new object clauses designed to pivot the company toward emerging sectors. These new clauses enable TAKE Limited to venture into healthcare technology, digital health solutions, diagnostics, pharmaceuticals, biotechnology, and clinical research. To formalize these changes, the board approved a Postal Ballot process, with the e-voting period scheduled to run from May 18, 2026, to June 16, 2026. This strategic shift aims to leverage the company’s existing life sciences expertise while expanding into higher-growth allied sectors.

TAKE Solutions operates primarily as a technology-driven healthcare solutions provider, focusing on life sciences and supply chain management. In early 2026, the company announced the launch of an Innovation Fund with an initial corpus of ₹5 Crores to support startups at the intersection of AI and healthcare. Recent developments in 2025 included a significant change in ownership, as Aakanksha Management Consultancy & Holdings Private Limited and Asia Global Trading (Chennai) Pvt Ltd each acquired 19% stakes in the company from TAKE Solutions Pte. Limited. The company has also recently forayed into the longevity and anti-aging segment, planning a portfolio of science-backed nutraceuticals and biohacking products.

For the quarter ended December 2025, the company reported a consolidated revenue of ₹1.46 Crores. This represented a significant decrease of approximately 78.9% compared to the previous quarter’s revenue of ₹6.92 Crores. Net profit for the same period stood at ₹1.11 Crores, reflecting an 82.35% decline from the ₹6.29 Crores recorded in the September 2025 quarter. Year-on-year, revenue fell by roughly 97.15% from the ₹51.31 Crores reported in the corresponding quarter of 2024. Famous investors or major institutional holdings are led by promoters and entities like Aakanksha Management Consultancy, which emerged as a key stakeholder in 2025.